Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Cisplatin and Gemcitabine vs Capecitabine in TNBC with Residual Disease
NCT06268327Phase 3Not yet recruiting
- Sponsor
- Assiut University
- Start
- Apr 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cisplatin and gemcitabine in triple-negative breast cancer (TNBC) (2 arms), sponsored by Assiut University. Primary endpoints: Efficacy of Adjuvant Cisplatin and Gemcitabine at 2 years and Toxicity at 2 years. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
cisplatingemcitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06268327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268327.